From signal to
clinical decision.
Across oncology, neurodegeneration, and drug development, Optomics® functions as a high-performance triage and stratification engine, bridging the gap between initial screening and definitive intervention.
50+
Validated
clinical sites
9
Countries
to date
3
Live indication
programs
Built on a proprietary biomarker library, Optomics resolves the biological ambiguity driving today's diagnostic bottlenecks: for clinicians, CROs, and drug developers alike.
1.5 million indeterminate nodules per year in the US. 40% of biopsies are negative. A rule-out filter before any invasive step.
Over 400 failed clinical studies. A $5,000+ PET scan to confirm amyloid burden. Pre-screening in under 30 seconds.
No validated screening exists for ovarian cancer. For high-risk women, the only option today is prophylactic surgery. Optomics® offers non-invasive stratification before that decision is forced.
One platform,
two streams of value.
Optomics® creates value across two critical axes and, for most clients, across both simultaneously.
A triage tool for smarter patient pathways.
A clinically pragmatic two-step pathway: a safety-first screening layer that rules out disease for the majority with high confidence. Second, evidence-based escalation ensuring costly procedures are reserved for patients most likely to benefit.
Fewer missed cases, fewer unnecessary tests, shorter time to definitive care.
Optimized stratification for faster trials.
Powered by the digital twin library, Optomics® delivers an objective, high-confidence risk stratification score supporting cohort enrichment, accelerated eligibility, and reduced screen failure - compressing the diagnostic interval from months to days.
Faster recruitment, improved cohort quality, more efficient study execution.
Optomics across indications and applications.
One platform. Three disease areas.
Check where and how Optomics® creates value.
Clinical trials
Patient pathways
Lung cancer
Oncology
Trials
· Cohort enrichment for targeted therapy trials
· Reduced screen-failure rate
· Objective eligibility scoring
Pathway
Diagnosis → Stratification → Monitoring
Alzheimer's
Neurodegeneration
Trials
· Amyloid / tau pre-screen before LP or PET
· ↓70% recruitment timeline
· ↓40% screening cost
Pathway
Diagnosis → Stratification → Monitoring
Ovarian cancer
Oncology
Trials
· Objective stratification beyond CA125
· Prioritization for oncology trial cohorts
Pathway
Diagnosis → Stratification → Monitoring
Lung
cancer:
the specificity crisis.
Lung cancer is the global leader in cancer mortality — survival below 25%, primarily due to late detection. Optomics® enters the pathway at the point where current tools fail.
1.5M
Indeterminate nodules / yr
In the U.S. alone
40%
Biopsies negative
For malignancy
<25%
Survival rate
Late detection
Rule-out
Filter
Before any invasive step
The Optomics® solution
A high-fidelity triage layer extracting molecular signatures of malignancy from a standard clinical blood draw - a rule-out filter before invasive follow-up.
Pathways
Eliminates unnecessary invasive procedures and the diagnostic anxiety gap while preventing clinical complications.
Trials
Accelerates eligibility decisions and reduces unnecessary radiation exposure in screening cohorts.
Alzheimer's: breaking the invasiveness barrier.
Alzheimer's affects 55 million people worldwide. 400+ clinical studies have failed in the last 20 years, in part because current screening tools make it prohibitively expensive to find the right patients.
~88%
screen failure rate
in Alzheimer's trials.
>50%
of trial costs
goes to screening
2
therapies
approved for early Alzheimer's.
<14%
patients eligible
for approved therapies
The Optomics® solution
A rapid, label-free pre-screening layer identifying nano-scale pathological signatures in plasma. High-confidence pre-screening score in under 30 seconds.
Pathways
A non-invasive rule-out step in primary care, before the disease progresses past the treatment window.
Trials
Filters out unlikely candidates before expensive confirmatory testing, protecting trial integrity.
Ovarian cancer: resolving ambiguity in the 'silent killer'
The most lethal gynecological malignancy - typically diagnosed at Stage III or IV. The primary obstacle is not the absence of markers, but their lack of specificity.
<35%
Survival
Stage III/IV at diagnosis
>90%
Survival
if detected at Stage I
19%
DETECTED AT EARLY STAGE
as sole stratification tool
Early detection
Rule-out
BEFORE PROPHYLACTIC SURGERY
The Optomics® solution
"High-dimensional optical fingerprints detecting malignant neoplasms at early stage, ultimately delaying prophylactic surgery".
Pathways
Drives detection toward Stage I, where survival exceeds 90%. Reduces unnecessary invasive diagnostic surgeries in benign conditions.
Trials
Empowers researchers to prioritize participants for oncology trials using objective stratification — moving beyond CA125 and traditional proteomic panels.
Take the next step.
Read the technical evidence behind Optomics®
Application notes, validation data, and methodology in one document.
See how Optomics fits your trial workflow.
Recruitment timelines, stratification scores, cohort quality - let's talk about your next study.
